Document is current
Any future updates will be listed below
-
Authors
Lang, Manlin
Liang, Ping
Shen, Huiming
Li, Hang
Yang, Ning
Chen, Bo
Chen, Yixu
Ding, Hong
Yang, Weiping
Ji, Xiaohui
Zhou, Ping
Cui, ligang
Wang, Jiandong
Xu, Wentong
Ye, Xiuqin
Liu, Zhixing
Yang, Yu
Wei, Tianci
Wang, Hui
Yan, Yuanyuan
Wu, Changjun
Wu, Yiyun
Shi, Jingwen
Wang, Yaxi
Fang, Xiuxia
li, Ran
Yu, Jie
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04657328 at ClinicalTrials.govDocuments that mention this clinical trial
Head-to-head comparison of perfluorobutane contrast-enhanced US and multiparametric MRI for breast cancer: a prospective, multicenter study
https://doi.org/10.1186/s13058-023-01650-3
-
Funding
Funding for this research was provided by:
National Scientific Foundation Committee of China (92159305, 82030047)
- License Information
-
More Information
Article History
Received: 21 October 2022
Accepted: 22 April 2023
First Online: 30 May 2023
Declarations
:
: The study was approved in the center of the principal investigator at Chinese PLA General Hospital in Beijing, China (IRB number: 2020-300). The Ethical Committee was “Chinese PLA General Hospital”. Approval was obtained on July 23rd, 2020. Every patient signed a written informed consent form in each center. The research was carried out in accordance with the Declaration of Helsinki.
: The authors declare that they have no competing interests.
